FilingReader Intelligence
Hengrui subsidiary gains clinical trial approval for cancer drug
August 14, 2025 at 05:03 PM UTC•By FilingReader AI
Jiangsu Hengrui Medicine's subsidiary Suzhou Sinomedica Bio-Pharmaceutical obtained approval from China's National Medical Products Administration for SHR-7782 injection clinical trials.
The in-house developed biological product targets cancer cell surface antigens to treat advanced solid tumors. Cumulative R&D investment totals approximately 48.2m yuan.
No similar drugs are currently approved globally.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Jiangsu Hengrui Medicine publishes news
Free account required • Unsubscribe anytime